Trial purpose
Cancer treatment
Tumor type
Haematological
Age
16 - 70
Clinical summary
Summary
All patients will receive peripheral blood stem cell transplant from haploidentical relatives. Patients will either undergo myeloablative or non- myeloablative conditioning treatments prior to receiving stem cell transplants. The conditioning treatment selected is determined by the transplant specialist. Two groups will then receive a treatment aimed at prevention of Graft versus Host disease after stem cell transplant. If you receive myeloablative conditioning treatment, your post-transplant treatment will include cyclophosphamide 50mg/kg administered on day 3 and day 4 after transplant with cyclosporine [dose calculated on body weight] and mycophenolate [dose calculated on body weight ] commencing on day 5 after transplant. If you receive non- myeloablative conditioning treatment, your post-transplant treatment will include cyclophosphamide 50mg/kg administered on day 3 and day 4 after transplant with tacrolimus [dose calculated on body weight] and mycophenolate [dose calculated on body weight] commencing on day 5 after transplant. Total duration of treatment will depend if graft versus host diseas develops and how severe. It is anticiapted adding cyclophosphamide post stem cell infusion will prevent Graft versus Host disease or affect the rate of acute and chronic Graft versus Host disease.
Conditions
This trial is treating people with blood cancer
Eligibility
Inclusion
1. Patients 16 – 70 years of age
2. Recipients must have a haematological malignancy with a significant risk of relapse (as measured by the Disease Risk Index), where allogeneic transplant is indicated.
3. Adults without a readily available matched related or unrelated donor.
4. Patients must have a first-degree relative who are 3/6 to 4/6 HLA matched.
5. Patients with an HCT-CI/age > or equal to 3 will receive non-myeloablative conditioning.
6. Adequate cardiac (LVEF >50%), pulmonary (DLCO/VA >50%) and renal function (Creatinine Clearance >60ml/min).
7. Informed written consent.
8. Haematological malignancies may be (but are not limited to):
a. AMLCR1 (high risk cytogenetics, FLT-3 positive), CR2
b. AML refractory disease with less than or equal 2 CIBMTR adverse risk factors.
c. tAML/MDS: with less than or equal 2 CIBMTR adverse risk factors
d. MDSIPSS Int-2/High risk
e. MPD eligible for HSCT
f. CML prior AP/BT in CP2; inadequate response to treatment of CP CML:
g. ALL CR1 (high risk cytogenetics or MRD+ve), CR2
h. Lymphoma (NHL or HL) in remission
Exclusion
1.Pregnancy.
2. Positive serology for HIV.
3. Refractory Central Nervous System (CNS) disease.
4. Serious organ dysfunction: LVEF <50%, FEV1, FVC, DLCO <50%of predicted, LFT > 5 x the upper limit of normal, or creatinine clearance < 40 ml/min .
5. Life expectancy less than 60 days.
6. Unable or unwilling to provide written informed consent
Exclusion
- You have certain types of non-cancer medical conditions.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:
Trial sponsor
St Vincents Hospital Sydney ,Arrow Bone Marrow Transplant Foundation
Scientific Title
A phase II study of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide as Graft versus Host Disease (GVHD) prophylaxis
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information